These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 33215952)

  • 41. The role of novel biologics in biliary cancers.
    Jordan E; Braghiroli MF; Lowery MA
    Minerva Gastroenterol Dietol; 2016 Dec; 62(4):325-339. PubMed ID: 27576672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy of biliary tract cancer.
    Chai Y
    Tumour Biol; 2016 Mar; 37(3):2817-21. PubMed ID: 26729196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.
    Mahmood RD; Graham K; Gleeson J; Hubner RA; Valle JW; McNamara MG
    Immunotherapy; 2023 May; 15(7):517-530. PubMed ID: 37009698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel Immunotherapy Combinations.
    Bashir B; Wilson MA
    Curr Oncol Rep; 2019 Nov; 21(11):96. PubMed ID: 31696332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current and emerging therapies for advanced biliary tract cancers.
    Kam AE; Masood A; Shroff RT
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An update on immunotherapy options for urothelial cancer.
    Bilgin B; Sendur MAN; Hizal M; Yalçın B
    Expert Opin Biol Ther; 2019 Dec; 19(12):1265-1274. PubMed ID: 31518156
    [No Abstract]   [Full Text] [Related]  

  • 49. Is there any place for novel agents in treating biliary tract cancer?
    Perego G; Burgio V; Nozza R; Longobardo G; Bernecich M; Luciani A; Petrelli F
    Med Oncol; 2021 Feb; 38(2):19. PubMed ID: 33543377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
    Lin ZF; Qin LX; Chen JH
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.
    Zeng FL; Chen JF
    Technol Cancer Res Treat; 2021; 20():15330338211039952. PubMed ID: 34528830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?
    Ricci AD; D'Alessandro R; Rizzo A; Schirizzi A; Vallarelli S; Ostuni C; Troiani L; Lolli IR; Lotesoriere C; Giannelli G
    Immunotherapy; 2023 May; 15(7):477-486. PubMed ID: 36950960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Clinical Trial Results of the Recently Approved Immunotherapeutic Drugs for Advanced Biliary Tract Cancers.
    Das S
    Rev Recent Clin Trials; 2024; 19(2):81-90. PubMed ID: 38288802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
    Piha-Paul SA; Oh DY; Ueno M; Malka D; Chung HC; Nagrial A; Kelley RK; Ros W; Italiano A; Nakagawa K; Rugo HS; de Braud F; Varga AI; Hansen A; Wang H; Krishnan S; Norwood KG; Doi T
    Int J Cancer; 2020 Oct; 147(8):2190-2198. PubMed ID: 32359091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy for the treatment of biliary tract cancer: an evolving landscape.
    Wilbur HC; Azad NS
    Ther Adv Med Oncol; 2024; 16():17588359241235799. PubMed ID: 38449562
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current progress in systemic therapy for biliary tract cancers.
    Sutherland M; Ahmed O; Zaidi A; Ahmed S
    J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1094-1107. PubMed ID: 33735541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer.
    Kim H; Kim R; Jo H; Kim HR; Hong J; Ha SY; Park JO; Kim ST
    Therap Adv Gastroenterol; 2022; 15():17562848221117638. PubMed ID: 35992188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.